This binding appears to be a key factor in Zfp106’s ability to mitigate the cytotoxic effects associated with GGGGCC repeats, highlighting its potential as a therapeutic target for C9ORF72-linked ALS and FTD [39]. This evidence concerns the gene C9orf72 and frontotemporal dementia.